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Capsule summary  
LRBA deficiency, a life-threatening immunodeficiency/autoimmunity disorder, was treated 
by HSCT in 12 patients, four of whom died from transplant-related causes. Six patients were 
cured without further need of immunosuppression, and two are in partial remission. 
 3 
To the Editor 1 
 2 
LPS-responsive beige-like anchor protein (LRBA)-deficiency is a severe primary 3 
immunodeficiency with a variable clinical phenotype, including features overlapping with 4 
common variable immunodeficiency, autoimmune lymphoproliferative syndrome, immune 5 
dysregulation polyendocrinopathy enteropathy X-linked (IPEX) syndrome, and an association 6 
with lymphoma1-3. Despite accumulating experience, the procedure of allogeneic 7 
hematopoietic stem cell transplantation (HSCT) to treat primary multi-organ autoimmunity 8 
disorders and combined immunodeficiencies with immune dysregulation such as LRBA 9 
deficiency is not routine. First, the indication and optimal time point are undetermined. 10 
Second, the outcome of HSCT in syndromes with predominant autoimmunity is unclear, 11 
given that target antigens of autoimmune reactions remain unchanged, and autoimmunity 12 
as well as inflammation may persist due to disease-causing factors extrinsic to the 13 
hematopoietic and immune system. For instance, LRBA is a ubiquitously-expressed protein 14 
functioning in autophagy and intracellular vesicle trafficking, facilitating cell surface 15 
translocation of CTLA44, 5. Its relevance in tissues other than immune cells is unknown.  16 
Augmentation of regulatory T cell function in LRBA-deficient individuals manifesting with 17 
chronic enteropathy by regular CTLA4-Ig infusions potentially induces remission4. However, 18 
not all symptoms respond equally, and patients remain dependent on CTLA4 substitution. 19 
Furthermore, the additional use of steroids, sirolimus, hydroxychloroquine, and other 20 
immunosuppressants may not prevent the long-term deterioration of patients with this 21 
potentially fatal disease. Finally, CTLA4-Ig is not available in many countries due to limited 22 
resources. Although HSCT has proven helpful in single patients1, 6-9, early reports of HSCT in 23 
cases of LRBA deficiency indicated a higher transplant-related mortality (TRM) than in other 24 
inborn errors (2 of first 4 patients); it is unclear whether disease status at time of HSCT or 25 
other disease- or transplant-related factors were involved. To better understand the role of 26 
HSCT as a potentially curative treatment for LRBA deficiency, we performed an international 27 
EBMT-, and ESID-wide survey in 2016 to collect information about the HSCT experience.  28 
Data were obtained in accordance with the Declaration of Helsinki and an Institutional Board 29 
review (IRB00002556, 29-142ex16/17) by retrospective chart review by the local physicians. 30 
From a cohort of 72 patients with LRBA deficiency, 12 underwent HSCT between 2005-2016 31 
(Table 1). Indications for transplant included refractory immune cytopenias, gastrointestinal 32 
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problems, parenchymal lung disease, failure to thrive, severe neurological or infectious 33 
complications, or plainly “severe course of the disease” (Table 1 and Figure 1A). Overall 34 
survival of transplanted patients was 67% (8/12 patients); all deaths were due to TRM (pre-35 
existing infections, graft failure, multi-organ failure, thrombotic microangiopathy) and 36 
occurred within three months of HSCT (Table 1, Figure 1, and Supplementary Figure 1). 37 
Eleven donors were HLA-matched unrelated or family donors (4 and 7, respectively). One of 38 
the deceased patients was the only subject of the cohort with a mismatched (haploidentical 39 
family) donor. Surviving patients showed mostly favorable degrees of remission (complete: 40 
4; good partial: 2 [some mild or moderate potentially LRBA-related symptoms, not requiring 41 
immunosuppressive therapy]; partial: 2 [amelioration of disease but need of 42 
immunosuppression for potentially LRBA-related symptoms]) with a median follow-up of 43 
23,5 months (range 4-142; Table 1 and Figure 1). HSCT course and recurrence or persistence 44 
of symptoms were apparently not dependent on the donor's LRBA status or on 45 
type/intensity of conditioning. All survivors in complete or good partial remission showed 46 
full donor chimerism (>95% donor white blood cells, WBC). Two patients with partial 47 
remission (requiring immunosuppressive treatment) showed declining donor WBC 48 
chimerism <90%: patient 3 had 89% donor WBC on day +240 and was treated with sirolimus 49 
and romiplostim for moderate immune thrombocytopenia, and patient 9, with only 7% WBC 50 
and 23% T cell chimerism on day +578, was treated with abatacept after attempts with 51 
steroids and rituximab for AIHA (see details in Table 1). Thus, best results of HSCT for LRBA 52 
deficiency were associated with full donor chimerism. Donor source, transplant regimen, 53 
GvHD incidence, and disease response are listed in Table 1 and Figure 1. Strikingly, LRBA-54 
related symptoms resolved or decreased significantly in number and intensity and 55 
performance scores increased in all HSCT survivors (Figure 1A-C). Consequently, the need for 56 
immunosuppressive treatment declined and most patients were off immunoglobulin 57 
replacement post-HSCT (Figure 1D-E). Unfortunately, there are no up-to-date follow-up and 58 
survival data of untransplanted patients beyond previous publications of large cohort 59 
studies, that reported at least six deceased of 58 untransplanted but many newly diagnosed 60 
patients and family members1, 2, 5. 61 
Although the number of patients surveyed was too small to routinely recommend HSCT for 62 
LRBA-deficiency based on the evidence collected, these data support the feasibility and 63 
curative potential of HSCT and allow us to state three important points.  64 
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First, remissions without further need for immunosuppression are achievable and occurred 65 
in 6 of the 8 surviving patients. No relapse occurred in patients with full donor chimerism. 66 
Importantly, although the treatment-requiring autoimmune cytopenias in patients 3 and 9 67 
observed after HSCT are possibly caused by LRBA deficiency due to waning donor chimerism, 68 
they could also be attributed to graft failure, post-HSCT immune dysregulation, or marrow 69 
dysfunction, like suspected in the growth factor responsive thrombocytopenia and 70 
neutropenia of patient 11, as such sequelae may similarly occur in HSCT recipients with 71 
other underlying diseases. With a median follow-up of 2 years, six of eight patients did not 72 
need further pharmacological immunosuppression or immunoglobulin replacement therapy, 73 
indicating curability. Only one patient in this cohort received abatacept as bridging 74 
treatment to HSCT. It is unclear whether response to abatacept would have changed the 75 
HSCT indication. However, despite the overall satisfying responses to abatacept (reported in 76 
10 patients in the cohort of 72 patients), the long-term dependency on this treatment with 77 
its associated potential risks remains. The risk of LRBA-related lymphoma or 78 
immunosuppression-associated malignancy would be anticipated to be substantially 79 
reduced or abolished in HSCT survivors, as well as the future risk of infections, as compared 80 
to patients undergoing continuous treatment with CTLA4-Ig, sirolimus or other 81 
immunosuppression. Thus, based on the present results, we would proceed to HSCT if a 82 
suitable donor is present. The optimal time point remains to be determined, but it can be 83 
expected that long-term organ damage will impact negatively on HSCT results.  84 
Second, among the small cohort of 12 LRBA-deficient patients who were transplanted from 85 
heterozygous LRBA mutation carriers (n=6), LRBA wild-type or unrelated donors (n=5), no 86 
correlation between residual or recurring LRBA-related symptoms and donor LRBA status 87 
was detected, arguing against a dosage effect of LRBA2, 6.  88 
Lastly, these data indicate that any alluded LRBA-dependent effects outside the 89 
(transplanted) hematopoietic/immune tissues play no or only an inferior role with regard to 90 
outcome and remission.  91 
Together, accepting the limitation that the retrospective case series lacked a matched 92 
control group, our findings strongly support the use of early HSCT in patients with severe 93 
presentations of LRBA deficiency. 94 
 95 
Supplemental Data are available in the Journal’s Online Repository at www.xxxyyyzzz.org. 96 
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Legends 136 
 137 
Table 1. Clinical characteristics and laboratory parameters of 12 LRBA-deficient patients 138 
who underwent allogeneic hematopoietic stem cell transplantation (HSCT). Abbreviations: 139 
(+3yrs) or (d+84) ,time point after HSCT; ADEM, acute disseminated encephalomyelitis; AdV, 140 
adenovirus; aGvHD, acute graft-versus-host disease; AIHA, autoimmune hemolytic anemia; 141 
AZT, azathioprine; cGvHD, chronic graft-versus-host disease; CMV, cytomegalovirus; CNS, 142 
central nervous system; CR, complete remission; CSA, cyclosporine A; CVID, common 143 
variable immunodeficiency; FK, tacrolimus/FK506; FU, follow-up; GCSF, granulocyte colony 144 
stimulating factor; GPR, good partial remission (mild residual symptoms- potentially LRBA-145 
related- but without requirement of immunosuppressive treatment); het, heterozygous; 146 
IDDM, insulin-dependent diabetes mellitus –in this case as sequelae after pancreatitis; IS, 147 
immunosuppressive drugs; IVIG, regular intravenous immunoglobulin replacement 148 
therapy;LRBA, lipopolysaccharid-responsive beige-like anchor protein; MFD, matched family 149 
donor; MMF, mycophenolate mofetil; MMFD, mismatched family donor; MSD, matched 150 
sibling donor; MTX, metothrexate; MUD, matched unrelated donor; n.d. ,no data or not 151 
determined; PR, partial remission (moderate residual symptoms- potentially LRBA-related- 152 
with requirement of immunosuppressive treatment); SC boost, stem cell boost; SCIG, regular 153 
subcutaneous immunoglobulin replacement therapy; steroids, glucocorticoids; T, B, T and B 154 
lymphocytes; TMA, thrombotic microangiopathy; TRA, thrombopoietin receptor agonist 155 
treatment; TRM, transplant-related mortality; WBC, white blood cells; wt, wild-type. 156 
 157 
 158 
Figure 1. Qualitative and semiquantitative assessment of disease activity of 12 patients 159 
with LRBA deficiency before and after hematopoietic stem cell transplantation. A, A heat 160 
map of LRBA-related symptoms is shown indicating symptom severity in patients before and 161 
after HSCT in pairs of columns (white: absent; light grey, mild-moderate; dark grey: severe 162 
and considered as HSCT indication; black columns indicate deceased patients). B, number of 163 
symptoms (as listed in A) before and after HSCT. C, Karnovsky/Lansky performance scores 164 
before and after HSCT; deceased patients were excluded from the analysis after HSCT. D, 165 
number of immunosuppressive drugs used simultaneously or sequentially for the treatment 166 
of LRBA-related symptoms before and after HSCT. E, immunoglobulin therapy shown as 167 
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none (bottom line); sporadic, indicating use as irregular immunomodulatory treatment 168 
(center level); or regular, indicating monthly intravenous or weekly subcutaneous 169 
replacement therapy (top).  170 
 171 
 172 
